Get started
Author

S H Chen

Observed names: S Chen, Su Chen
Observed institution: AbbVie (United States)
OpenAlex ID: A5123483633
DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study
2026 · R Atreya, E Louis, et al. · Journal of Crohn s and Colitis · 1
P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results
2026 · Raja Atreya, Edouard Louis, et al. · E-Posters
P1073 Real-World Effectiveness, Symptomatic Improvement, and Safety of Upadacitinib in Patients With Moderate-to-Severe Ulcerative Colitis: Interim Findings From the PROFUNDUS Study
2026 · R Panaccione, M Fumery, et al. · Journal of Crohn s and Colitis
PDF
P0742 A Postmarketing, Prospective, Noninterventional Study Evaluating the Real-World Clinical Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease: Interim Results From the APPRISE Study
2026 · P Bossuyt, T Hisamatsu, et al. · Journal of Crohn s and Colitis
Works count: 4
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type